Skip to main content

Table 4 Association of statin exposure (cumulative supply) with normalized FG from all statin users and those with normal FG (< 100) within 2 years prior to statin initiation, by statin typeb, filtered for all drugs

From: Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort

Prior FG

Statin Type

Number of individuals

Number of observations

Regress coeff (S.E.)

p-value (R2)

All

All

25,134

106,913

0.00512 (0.00046)

5.38E−29 (0.0012)

Simva

8166

31,681

0.00546 (0.00108)

4.04E−07 (0.0008)

Lova

14,327

69,222

0.00463 (0.00053)

4.88E−18 (0.0011)

Atorva

2339

5231

0.00656 (0.00327)

4.52E−02 (0.0008)

Normal (< 100)

All

11,496

49,415

0.00976 (0.00069)

2.19E−45 (0.0040)

Simva

3765

14,471

0.00908 (0.00168)

7.21E−08 (0.0020)

Lova

6542

32,309

0.00883 (0.00080)

2.43E−28 (0.0038)

Atorva

1051

2280

0.01245 (0.00485)

1.02E−02 (0.0029)

  1. aAdjusted for covariates age, sex, BMI, race/ethnicity and average FG level during the 5 years prior to start of statin
  2. bAdjusted for covariates age, sex, BMI, race/ethnicity and average FG during the 5 years prior to start of statin